Related Experiment Video

Updated: May 9, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3

Yi Zhang1, Qiping Lu, Xun Cai

  • 1Department of General Surgery, Wuhan General Hospital of Guangzhou Command, 627#, Wuluo Road, Wuhan 430070, China.

FEBS Letters
|August 13, 2013
PubMed

Insights

MicroRNA-106a (miR-106a) promotes multidrug resistance (MDR) in gastric cancer (GC) by increasing chemotherapy resistance and reducing apoptosis. It targets RUNX3, offering a potential therapeutic target for overcoming MDR in GC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multidrug resistance (MDR) is a significant challenge in gastric cancer (GC) chemotherapy.
  • MicroRNA-106a (miR-106a) is upregulated in GC and its role in MDR is not fully understood.

Purpose of the Study:

  • To investigate the function of miR-106a in the multidrug resistance of gastric cancer.
  • To identify the molecular mechanisms underlying miR-106a's role in GC chemoresistance.

Main Methods:

  • Comparison of miR-106a expression in multidrug-resistant GC cell lines versus sensitive ones.
  • Assessment of miR-106a's effects on chemoresistance, drug efflux, and apoptosis in GC cells.
  • Identification and validation of runt-related trans factor 3 (RUNX3) as a direct target of miR-106a.

Main Results:

  • miR-106a expression is significantly elevated in multidrug-resistant GC cell lines.
  • Overexpression of miR-106a enhances chemoresistance, promotes Adriamycin (ADR) efflux, and inhibits drug-induced apoptosis in GC cells.
  • RUNX3 was confirmed as a functional target of miR-106a.

Conclusions:

  • miR-106a promotes multidrug resistance in gastric cancer cells.
  • The mechanism involves the targeting of RUNX3, leading to increased chemoresistance and reduced apoptosis.
  • Targeting the miR-106a/RUNX3 axis may represent a novel therapeutic strategy for overcoming MDR in GC.
Keywords:
Gastric cancerMultidrug resistanceRunt-related transcription factor 3miR-106a

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...